默沙东花超200亿元引进礼新医药PD-1双抗，南京蓬勃将获分成

中新经纬11-15

中新经纬11月15日电 (王玉玲)14日，默沙东中国公众号发文称，默沙东已协议获得礼新医药科技有限公司(下称礼新医药)在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。以此计算，本次默沙东与礼...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483439413?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-15 15:51","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483439413","market":"us","top_or_hot":-1,"title":"默沙东花超200亿元引进礼新医药PD-1双抗，南京蓬勃将获分成","media":"中新经纬","content":"<div>\n<p>中新经纬11月15日电 (王玉玲)14日，默沙东中国公众号发文称，默沙东已协议获得礼新医药科技有限公司(下称礼新医药)在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。以此计算，本次默沙东与礼...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东花超200亿元引进礼新医药PD-1双抗，南京蓬勃将获分成</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东花超200亿元引进礼新医药PD-1双抗，南京蓬勃将获分成\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 15:51 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b><strong>中新经纬</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中新经纬11月15日电 (王玉玲)14日，默沙东中国公众号发文称，默沙东已协议获得礼新医药科技有限公司(下称礼新医药)在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。以此计算，本次默沙东与礼...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b","article_id":"2483439413","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115155335a23a3cb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483439413","pubTimestamp":1731657063,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。2024年二季度报显示，默沙东在肿瘤领域的研发管线包括多款ADC产品，MK-1022、MK-2870、MK-2400等，以及PD-1与其他药物的双免方案开发，例如LAG-3抗体MK-4280、抗CTLA-4抗体MK-1308等。15日早间，金斯瑞生物科技发布公告称，该公司获悉，默沙东与礼新医药已订立独家全球许可。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","BK4516":"特朗普概念","LU0058720904.USD":"联博国际健康护理基金A","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","MRK":"默沙东","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999001176.USD":"United Global Healthcare Acc USD","BK4559":"巴菲特持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC"},"translate_title":"Merck spent more than 20 billion yuan to introduce Lixin Pharmaceutical PD-1 dual antibody, and Nanjing Booming will receive a share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"MRK":1},"content_text":"中新经纬11月15日电 (王玉玲)14日，默沙东中国公众号发文称，默沙东已协议获得礼新医药科技有限公司(下称礼新医药)在研PD-1/VEGF双特异性抗体LM-299的全球开发、生产和商业化独家许可。交易对价超200亿元据默沙东中国，礼新医药将获得5.88亿美元的首付款。基于LM-299多项适应证的技术转让、开发、获批和商业化进展，礼新医药还将获得最高27亿美元的里程碑付款。以此计算，本次默沙东与礼新医药的交易总价值最高可达32.88亿美元(约合237.86亿元人民币)。LM-299是一种在研PD-1(细胞程序性死亡因子)/VEGF(血管内皮生长因子)双特异性抗体。目前，LM-299的I期临床试验正在中国招募受试患者。2024年二季度报显示，默沙东在肿瘤领域的研发管线包括多款ADC产品，MK-1022、MK-2870、MK-2400等，以及PD-1与其他药物的双免方案开发，例如LAG-3抗体MK-4280、抗CTLA-4抗体MK-1308等。今年5月末，康方生物医药有限公司(下称康方生物)宣布，该公司PD-1/VEGF双抗新药依沃西单抗注射液(商品名：依达方)与默沙东明星产品帕博利珠单抗进行头对头试验。康方生物称，HARMONi-2研究数据表明，在意向治疗人群(ITT)中，依沃西组相较于帕博利珠组显著延长了患者无进展生存期(PFS)，风险比(HR)显著优于预期。依沃西成为全球首个且唯一在III期单药头对头临床研究中证明疗效显著优于帕博利珠单抗的药物。2022年末时，康方生物将依沃西在指定区域的开发和商业化独家许可权授权给代理商Summit Therapeutics。2024年6月，康方生物又与前述公司签署补充许可协议，继续拓展依沃西的许可市场范围。对于本次引进礼新医药双抗，默沙东中国称，该公司持续寻找机会，扩大并丰富肿瘤在研管线，覆盖差异化机制和多种疗法。该协议扩充了默沙东肿瘤管线，期待快速严谨地推进LM-299的开发。礼新医药是一家生物制药公司，专注于开发研发肿瘤特异性靶向ADC和免疫调节大分子创新药物，近两年来，礼新医药完成融资与多项对外授权合作。除了默沙东外，礼新医药在2023年5月宣布与阿斯利康就临床前阶段的ADC药物LM-305项目达成全球独家授权协议。据默沙东中国，本次拟议交易在完成前需根据美国《哈特-斯科特-罗迪诺反垄断改进法案》和其他惯例条件获得批准。该交易预计将于2024年第四季度完成。金斯瑞生物科技子公司将获分成此外，从本次默沙东与礼新医药合作中受益的还有港股上市公司金斯瑞生物科技有限公司(下称金斯瑞生物科技)。15日早间，金斯瑞生物科技发布公告称，该公司获悉，默沙东与礼新医药已订立独家全球许可。在此之前，金斯瑞生物科技的非全资子公司南京蓬勃生物科技有限公司(下称南京蓬勃)与礼新医药达成就若干披露抗PD-1单域抗体的专利和相关专有技术的授权合作。金斯瑞称，据公司了解，LM-299包含了LaNova(即礼新医药)从南京蓬勃获得许可的抗PD-1单域抗体。根据此前南京蓬勃与礼新医药签订的经重述及经修订协议及确认函，礼新医药应在该公司首次发生与许可产品的开发和监管批准相关的各项里程碑事件时向南京蓬勃支付若干预付款和里程碑付款。南京蓬勃亦有权从礼新医药就关于许可的任何再许可实际收到的再许可收益中获得一定比例的收益。具体而言，(其中包含)就首个开发的授权产品，南京蓬勃将有权获得与在新药研究申请批准后、许可产品一期临床试验完成前的任何再许可相关的40%的预付款和25%的其他里程碑付款，及礼新所收特许使用费(收入分成)中的25%。中新经纬以5.88亿美元(约合42.53亿元人民币)计算，若按照40%预付款比例计算，则南京蓬勃可以从预付款中获得2.35亿美元(约合17.00亿元人民币)提成。截至中新经纬发稿，金斯瑞生物科技报每股11.64港元，涨7.58%。(更多报道线索，请联系本文作者王玉玲：wangyuling@chinanews.com.cn)(中新经纬APP)(文中观点仅供参考，不构成投资建议，投资有风险，入市需谨慎。)中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其他方式使用。责任编辑：罗琨 李中元来源：中新经纬编辑：张澍楠广告等商务合作，请点击这里未经过正式授权严禁转载本文，侵权必究","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483439413"}